Alzhyme Pty Ltd is a biotechnology company based in Perth, Western Australia.
Alzhyme has been active in Alzheimer’s disease research since 2002.
Alzheimer’s disease is the most common form of dementia, accounting for 60-70% of diagnosed cases; it is estimated that 44 million people worldwide have dementia.
There is a dire need for better diagnostics and treatments for Alzheimer’s disease.
|Alzhyme is developing a novel therapeutic that aims to stop the progression of Alzheimer’s disease
Alzhyme is developing a novel therapeutic that has neuroregenerative potential for the treatment of neurodegenerative diseases
Alzhyme is developing a novel diagnostic that aims to diagnose Alzheimer’s disease at an earlier stage in the disease process
For more information, please contact us by filling in the information below.
Alzhyme Pty Ltd L1,
45 Stirling Hwy NEDLANDS
WA 6009 AUSTRALIA